MacroGenics, Inc. (NASDAQ:MGNX) Shares Purchased by XML Financial LLC

XML Financial LLC raised its position in MacroGenics, Inc. (NASDAQ:MGNX) by 31.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,169 shares of the biopharmaceutical company’s stock after purchasing an additional 5,569 shares during the period. XML Financial LLC’s holdings in MacroGenics were worth $75,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. XTX Topco Ltd purchased a new position in shares of MacroGenics during the third quarter valued at approximately $37,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of MacroGenics by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,064 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 4,707 shares during the period. Sanders Morris Harris LLC acquired a new stake in shares of MacroGenics during the fourth quarter worth $40,000. SG Americas Securities LLC purchased a new stake in shares of MacroGenics in the third quarter valued at $55,000. Finally, Intech Investment Management LLC purchased a new stake in shares of MacroGenics in the third quarter valued at $68,000. 96.89% of the stock is owned by institutional investors and hedge funds.

MacroGenics Stock Performance

MacroGenics stock opened at $3.16 on Friday. The firm has a market capitalization of $198.33 million, a PE ratio of -2.00 and a beta of 2.04. MacroGenics, Inc. has a one year low of $2.91 and a one year high of $21.88. The stock’s 50 day moving average price is $3.31 and its 200 day moving average price is $3.67.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MGNX. JMP Securities lowered MacroGenics from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 7th. StockNews.com upgraded shares of MacroGenics from a “sell” rating to a “buy” rating in a report on Sunday, November 10th. Finally, HC Wainwright restated a “neutral” rating and set a $4.00 price objective on shares of MacroGenics in a report on Wednesday, November 6th. Eight investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.63.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.